<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334604</url>
  </required_header>
  <id_info>
    <org_study_id>AAD2017</org_study_id>
    <nct_id>NCT03334604</nct_id>
  </id_info>
  <brief_title>The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children.</brief_title>
  <official_title>The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Winclove Probiotics B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, the investigators aim to assess the effectiveness of a multispecies probiotic&#xD;
      consisting of 2 strains of Bifidobacterium (B. bifidum W23, B. lactis W51) and 6 strains of&#xD;
      Lactobacillus (L. acidophilus W37, L. acidophilus W55, L. paracasei W20, L. plantarum W62, L.&#xD;
      rhamnosus W71, and L. salivarius W24) in reducing the risk of antibiotic-associated diarrhoea&#xD;
      in a group of children undergoing antibiotic therapy for common infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Certain individual probiotic strains have been proven to be effective in reducing the risk of&#xD;
      antibiotic-associated diarrhoea (AAD). However, the effects of using multispecies probiotics&#xD;
      remain unclear. The investigators aim to assess the effectiveness of a specific multispecies&#xD;
      probiotic preparation (Ecologic AAD Kids) in reducing the incidence of AAD in children.&#xD;
&#xD;
      In this trial, a total of 350 children aged 3 months to 18 years, undergoing antibiotic&#xD;
      treatment, will be randomly allocated to receive either a multispecies probiotic consisting&#xD;
      of 2 strains of Bifidobacterium (B. bifidum W23, B. lactis W51) and 6 strains of&#xD;
      Lactobacillus (L. acidophilus W37, L. acidophilus W55, L. paracasei W20, L. plantarum W62, L.&#xD;
      rhamnosus W71, and L. salivarius W24) at a total dose of 10^10 colony-forming units daily, or&#xD;
      a placebo, from the first day of antibiotic treatment until 7 days after antibiotic&#xD;
      cessation. The primary outcome measure will be the incidence of AAD, defined as ≥3 loose or&#xD;
      watery stools (a score of A on the Amsterdam Infant Stool Scale for children younger than 1&#xD;
      year and a score of 5-7 on the Bristol Stool Form scale for children older than 1 year) in 24&#xD;
      hours, caused either by Clostridium difficile or of otherwise unexplained aetiology (after&#xD;
      testing for common diarrhoeal pathogens), occurring during and/or up to 7 days after the end&#xD;
      of the antibiotic therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2018</start_date>
  <completion_date type="Actual">May 13, 2021</completion_date>
  <primary_completion_date type="Actual">May 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of antibiotic-associated diarrhea</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
    <description>Antibiotic-associated diarrhea will be defined as 3 or more loose or watery stools (a score of A on the Amsterdam Infant Stool Scale or 5-7 on the Bristol Stool Form scale) per day in a 24-hour period, caused by C. difficile infection or of otherwise unexplained aetiology after testing for common diarrhoeal pathogens (rotavirus, adenovirus, norovirus, Campylobacter spp., Salmonella spp., Shigella spp., and Yersinia spp.), occurring during the intervention period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibiotic-associated diarrhea - alternative definition 1</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
    <description>≥3 loose or watery stools per day for a minimum of a 48-hour period caused by C. difficile infection or of otherwise unexplained aetiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibiotic-associated diarrhea - alternative definition 2</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
    <description>≥2 loose or watery stools per day for a minimum of a 24-hour period caused by C. difficile infection or of otherwise unexplained aetiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of diarrhea</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
    <description>≥3 loose or watery stools per day for a minimum of 24 hours regardless of its aetiology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile-associated diarrhea</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
    <description>≥3 loose or watery stools per day for a minimum of 24 hours caused by C. difficile confirmed by the presence of toxin-producing C. difficile in stools.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of diarrhea</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
    <description>Defined as the time until the normalisation of stool consistency according to the Bristol Stoo Form (BSF) or Amsterdam Infant Stool Scale (AISS) - on BSF numbers 1, 2, 3 and 4; on AISS scale, letters B or C, and the presence of normal stools for 48 h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of the antibiotic treatment due to severity of diarrhoea</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation caused by diarrhoea</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for intravenous rehydration</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 7th day after antibiotic cessation.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">350</enrollment>
  <condition>Antibiotic-associated Diarrhea</condition>
  <arm_group>
    <arm_group_label>Multispecies probiotic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>175 participants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>175 participants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Multispecies probiotic</intervention_name>
    <description>Multispecies probiotic consisting of Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W55, Lactobacillus paracasei W20, Lactobacillus plantarum W62, Lactobacillus rhamnosus W71 and Lactobacillus salivarius W24 at a dose of 5x10^9 Colony Forming Units (CFU), twice daily, orally.</description>
    <arm_group_label>Multispecies probiotic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo identical in taste, smell and color to the multispecies probiotic.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  children receiving oral or intravenous antibiotics for common infections, willing and&#xD;
             able to start the probiotic intervention within 24 hours after the start of antibiotic&#xD;
             intake, receiving broad-spectrum antibiotics (broad-spectrum penicillins,&#xD;
             cephalosporins, fluoroquinolones, clindamycin).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior use of antibiotics within the previous 4 weeks, presence of a severe or&#xD;
             generalised infection, history of severe chronic disease (e.g., cancer, inflammatory&#xD;
             bowel disease, tuberculosis), critical/life-threatening illness, immunodeficiency,&#xD;
             history of pre-existing diarrhoea within the previous 4 weeks, exclusive&#xD;
             breastfeeding, allergy or hypersensitivity to any component of the study product,&#xD;
             tube-feeding, use of proton-pump inhibitors, laxatives or anti-diarrhoeal drugs, as&#xD;
             well as use of a probiotic product containing L rhamnosus GG or S boulardii 14 days&#xD;
             before and during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Łukasik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Paediatrics, The Medical University of Warsaw, Poland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLVG location West</name>
      <address>
        <city>Amsterdam</city>
        <zip>1061</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG location East</name>
      <address>
        <city>Amsterdam</city>
        <zip>1092</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics, St. Hedwig of Silesia Hospital</name>
      <address>
        <city>Trzebnica</city>
        <state>Silesia</state>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Paediatrics, The Medical University of Warsaw, Poland</name>
      <address>
        <city>Warsaw</city>
        <zip>02-091</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibiotic-associated diarrhea</keyword>
  <keyword>probiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data collected in the course of this study are available from the Principal Investigator upon reasonable request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

